Generation and Characterization of Human Monoclonal Antibodies Targeting Anthrax Protective Antigen following Vaccination with a Recombinant Protective Antigen Vaccine

Clinical and Vaccine Immunology : CVI
Xiangyang ChiWei Chen

Abstract

The anthrax protective antigen (PA) is the central component of the three-part anthrax toxin, and it is the primary immunogenic component in the approved AVA anthrax vaccine and the "next-generation" recombinant PA (rPA) anthrax vaccines. Animal models have indicated that PA-specific antibodies (AB) are sufficient to protect against infection with Bacillus anthracis. In this study, we investigated the PA domain specificity, affinity, mechanisms of neutralization, and synergistic effects of PA-specific antibodies from a single donor following vaccination with the rPA vaccine. Antibody-secreting cells were isolated 7 days after the donor received a boost vaccination, and 34 fully human monoclonal antibodies (hMAb) were identified. Clones 8H6, 4A3, and 22F1 were able to neutralize lethal toxin (LeTx) both in vitro and in vivo. Clone 8H6 neutralized LeTx by preventing furin cleavage of PA in a dose-dependent manner. Clone 4A3 enhanced degradation of nicked PA, thereby interfering with PA oligomerization. The mechanism of 22F1 is still unclear. A fourth clone, 2A6, that was protective only in vitro was found to be neutralizing in vivo in combination with a toxin-enhancing antibody, 8A7, which binds to domain 3 of PA and PA oligomers...Continue Reading

References

May 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·S H Leppla
Feb 27, 1997·Nature·C PetosaR C Liddington
Nov 9, 2001·Nature·K A BradleyJ A Young
Jan 16, 2003·Biochemical Pharmacology·Kenneth A Bradley, John A T Young
Mar 21, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Carlos P TabordaArturo Casadevall
Apr 17, 2004·Journal of Immunological Methods·Shane CrottyRafi Ahmed
May 14, 2004·Journal of Immune Based Therapies and Vaccines·Ritsuko Sawada-HiraiAngray S Kang
Oct 11, 2005·Proceedings of the National Academy of Sciences of the United States of America·Vladimir A KarginovSergey M Bezrukov
Feb 3, 2006·The Journal of Infectious Diseases·Zhaochun ChenRobert Purcell
Feb 8, 2006·Biochemical and Biophysical Research Communications·Jun ZhangWei Chen
Feb 7, 2007·Vaccine·Jessica A ChichesterVidadi Yusibov
Mar 6, 2007·Annual Review of Biochemistry·John A T Young, R John Collier
Feb 28, 2009·Nature Protocols·Kenneth SmithPatrick C Wilson
Aug 12, 2009·Molecular Aspects of Medicine·Fiorella Tonello, Cesare Montecucco
Aug 26, 2009·Infection and Immunity·Cassandra D Kelly-Cirino, Nicholas J Mantis
Jun 11, 2010·The Journal of Infectious Diseases·Sherry R CroweJudith A James
Nov 10, 2011·Toxins·Zhaochun ChenRobert Purcell
Jul 25, 2012·Proceedings of the National Academy of Sciences of the United States of America·Arturo Casadevall, Alena Janda
Apr 23, 2013·Cell Host & Microbe·Siu-Kei ChowArturo Casadevall
Aug 30, 2013·Expert Review of Vaccines·Manpreet KaurRakesh Bhatnagar
May 9, 2014·Infection and Drug Resistance·Carlos E Kummerfeldt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.